A potential $54 billion bid by Sanofi-Aventis for Bristol-Myers Squibb reportedly is being hobbled by a dispute among top Sanofi executives. Sanofi chairman Jean-Francois Dehecq is said to favor a transformational deal with Bristol-Myers, while CEO Gerard Le Fur emphasizes a focus on the group's internal drug R&D program.

Related Summaries